Researchers identified ST8Sia6, an immune-regulating molecule, as a potential explanation for treatment-resistant IBD. The study found that the absence of ST8Sia6 led to increased inflammation in preclinical models.
Dr. Gianrico Farrugia will complete his tenure as Mayo Clinic President and CEO in December, leaving a legacy of strategic advancement and innovation. The institution has accelerated disease cures, connected people with data, and transformed healthcare through its AI-enabled care transformation platform.
The study identifies nine distinct cellular neighborhoods in the tumor microenvironment, each associated with survival and immunotherapy response outcomes. The blood-based liquid biopsy test could guide treatment decisions for multiple cancer types and treatments.
A study published in JHLT Open found that remote patient monitoring can detect early health changes and support care decisions for lung transplant recipients. The system generated nearly 470 alerts, with most prompting changes in care, such as clinic visits or medication adjustments.
The Mayo Clinic AI model detects pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis, identifying subtle signs of disease. The model identified 73% of prediagnostic cancers at a median of about 16 months before diagnosis.
A new study from Mayo Clinic suggests that Alzheimer's disease may start as early as the late 50s, with subtle biological changes accelerating over time. Researchers analyzed data from 2,082 participants and found that biomarkers of tau pathology and neurodegeneration show more pronounced increases around ages 68 to 72.
A Mayo Clinic study found that bariatric surgery reduces long-term cardiovascular risk more effectively than weight-loss medications. The study analyzed outcomes for 812 adults with obesity and found that greater weight loss led to larger reductions in lifetime cardiovascular risk.
Researchers at Mayo Clinic have developed a blood-based method to detect germ cell tumors, the most common type of testicular cancer, including cases that do not show up on standard blood tests. The new test, GCT-iSIGN, identified 93% of individuals with germ cell tumors and correctly ruled out cancer in 99% of those without.
Researchers treated seven patients with advanced heart disease and difficult-to-treat ventricular tachycardia. The therapy resulted in a 79% reduction in VT episodes, with no serious treatment-related side effects during follow-up of up to two years. Proton beam therapy offers a new approach for patients with limited treatment options.
A Mayo Clinic study provides preclinical evidence for a targeted approach to managing immune-related kidney inflammation triggered by immunotherapy. The findings suggest that TNF-alpha blockade may improve markers of kidney injury and could be explored as a preventive measure.
Rosa Rademakers' groundbreaking discovery of the C9orf72 hexanucleotide repeat expansion revealed a common genetic origin for ALS and frontotemporal dementia, transforming how scientists study and diagnose these conditions.
Researchers at Mayo Clinic have developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, improving survival rates in preclinical models of glioblastoma. The approach uses small lipid-based particles to target tumor cells and enhance the impact of radiation therapy.
A new technique identifies proteins that trigger strong immune responses, challenging a common assumption in the field. The ratio of immunogenicity measurement reveals patterns among hundreds of proteins, highlighting mitochondrial proteins as particularly immunogenic.
A new study published in Mayo Clinic Proceedings found that robotic bronchoscopy has a high sensitivity for malignancy (85%) and accuracy rate (76.9%), with a complication rate of 2.8%. The technology allowed for earlier detection of lung cancer, reducing diagnoses at advanced stages from 54% to 31%, and improved survival rates.
A Mayo Clinic study found that AI-derived heart fat measurement can predict cardiovascular events more accurately when combined with traditional risk assessment approaches. The measurement significantly improved long-term risk prediction, especially among patients at low-risk categories.
Researchers at Mayo Clinic found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer reduced cancer recurrence and mortality by 50% compared to chemotherapy alone. The study used an immune checkpoint inhibitor, atezolizumab, to reactivate a person's anti-tumor immunity.
A Mayo Clinic study found that wearable sleep data can improve the prediction of patient engagement in a 12-week home pulmonary rehabilitation program. By combining baseline sleep data with machine learning and traditional clinical indicators, clinicians can tailor more effective care plans for patients with COPD.
Researchers found that vitamin D supplementation was associated with increased levels of immunoglobulin A and decreased levels of immunoglobulin G, indicating a more balanced immune response. The study also observed changes in immune signaling pathways and increased activity of regulatory immune cells.
A Mayo Clinic study shows that delivering chemotherapy at home is safe and feasible, reducing physical, emotional, and financial burdens associated with cancer treatment. Patients experienced fewer disruptions to daily life while maintaining a continuous connection with their care team through virtual visits and remote monitoring.
Researchers developed a targeted genetic therapy using milk-derived nanoparticles to attack cancer cells while sparing healthy tissue. The approach shows promise in treating aggressive bile duct cancer with limited treatment options.
The Mayo Clinic team developed a quantum-powered model that can detect movement intention from brain activity, potentially helping people with paralysis. The achievement marks one of Mayo Clinic's first end-to-end clinical applications of quantum computing.
Researchers identified a drug-and-supplement combination therapy that reduces senescent cells, inflammation, and injury in diabetic kidney disease. The treatment approach involves senolytics, which selectively target senescent cells.
Mayo Clinic researchers have identified a hidden 'movement map' deep within the brain, which could help surgeons reduce side effects from epilepsy procedures and guide future treatments for speech and movement disorders. The discovery was made using advanced brain-recording technology to create individualized maps of patients' brains.
A Mayo Clinic study found that women with abnormal Parkinson's-related protein levels accumulate Alzheimer's-related pathology faster, leading to faster disease progression. The study analyzed data from 415 participants and showed that women's brains progress up to 20 times faster than men's in this regard.
Researchers identified specific DNA-level changes in AD brains that affect oligodendrocyte function and tau protein levels. The study's findings may open new avenues for understanding neurodegenerative diseases and developing future therapies.
A Mayo Clinic study found that a single dose of non-prescribed Adderall can have measurable cardiovascular effects in healthy young adults, including significant increases in blood pressure and heart rate. The study highlights the risks of unsupervised use of stimulants like Adderall.
Researchers developed a new immunotherapy strategy by pairing next-generation therapy with standard hormone therapy before surgery, reducing Treg levels inside tumors and improving patient outcomes. The study provides clinical evidence for the effectiveness of engineered anti-CTLA-4 therapies in early-stage prostate cancer treatment.
Dr. Eric Moore, M.D., has been elected as a member of the Mayo Clinic Board of Trustees, bringing his extensive experience in head and neck surgery to guide strategic priorities. He is also a pioneer in less invasive transoral robotic surgery and has improved outcomes for patients with head and neck cancers.
Mayo Clinic has been ranked as the No. 1 hospital in the world for its eighth consecutive year by Newsweek, based on patient survey results and key performance metrics. The organization is transforming healthcare through its Bold. Forward. strategy, which combines deep clinical expertise with responsible digital innovation.
A Mayo Clinic study found that the brain enters a deep sleep state after a seizure, mimicking memory storage and strengthening disease. This phenomenon, called seizure-related consolidation, could help explain why epilepsy worsens over time and why memory and mood problems are common in people with the condition.
The collaboration will utilize Mayo Clinic Platform's secure infrastructure to analyze de-identified patient data from both institutions, enhancing research and driving innovation in healthcare. With access to over 15 million patients, the partnership aims to predict illness earlier, improve outcomes, and deliver more proactive care.
The Mayo Clinic Representative Office in the Cayman Islands will help patients make appointments at Mayo Clinic locations worldwide. The staff also assist with travel arrangements, billing, and insurance coordination, providing free services to patients and their families.
Researchers found that regulatory T cells can be redirected to protect tumors instead of the body. Blocking P2RX7, a molecule released by stressed cells, helps immune cells work more closely with B cells and leads to better outcomes.
The collaboration aims to integrate Mayo Clinic's clinical insights and genomic data with Merck's AI capabilities to support drug discovery and development. The partnership will focus on high-need therapeutic areas, leveraging multimodal data sets and advanced analytics to advance progress in disease treatment.
The Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US. This innovative technology uses heat to damage and kill cancer cells, offering a new angle in cancer treatment and potentially improving outcomes for patients with resistant tumors.
A medication commonly used to treat overactive bladder significantly reduced hot flashes in men receiving hormone therapy for prostate cancer. Men who took oxybutynin also reported improvements in day-to-day functioning and overall quality of life.
Researchers discovered that combining brigatinib with PARP inhibitors is more effective in killing ovarian cancer cells by blocking their survival response. Brigatinib targets key signaling molecules FAK and EPHA2, which aggressive ovarian cancer cells rely on to survive.
The two organizations are expanding their collaboration to improve care for neurodegenerative disease, prostate cancer, and metastatic liver tumors through enhanced imaging and interventional technologies. This expanded partnership aims to bring more precise, less invasive, and personalized treatment approaches to patients.
The integration of OMOP Oncology into Mayo Clinic Platform enables faster analysis of complex cancer data, unlocking deeper insights and accelerating research. This expansion supports the development of next-generation therapies for patients worldwide.
Researchers found that when pancreatic tumors touch the superior mesenteric vein, patients who undergo surgery first experience reduced survival rates. In contrast, those who receive chemotherapy before surgery have similar survival outcomes to those with non-vein touching tumors. The study suggests reclassifying tumors based on vein i...
Researchers developed a gene-editing therapy that directly corrects genetic mutations responsible for autosomal dominant polycystic kidney disease, slowing cyst growth and improving health outcomes. The therapy uses CRISPR-based base editing to precisely correct single-letter DNA mutations in the PKD1 gene.
A global study of 17,494 people from 158 countries reveals a significant gap between expected and experienced perimenopause symptoms. Fatigue, mood changes, and sleep-related issues are the most common reported symptoms, with exhaustion and fatigue being particularly prevalent.
A new study published in The Lancet Obstetrics, Gynaecology, & Women's Health found that postmenopausal women receiving hormone therapy lost 35% more weight while taking tirzepatide, a GLP-1-based obesity medication. This research could help develop personalized strategies for managing cardiometabolic risk in postmenopausal women.
Researchers used CT scans and AI to find links between poorer abdominal muscle measures and higher incidence of falls in middle-aged adults. Maintaining good core strength throughout adulthood may provide benefits that start in midlife and continue into older adulthood.
A new oral contrast agent significantly improves visualization of inflammatory bowel disease (IBD) or cancer within the abdomen, according to clinical trial data. The dark borosilicate agent reveals previously impossible-to-detect findings, including small bowel tumors and subtle inflammatory conditions.
A new study from Mayo Clinic introduces MedEduChat, an EHR-integrated AI agent providing accurate and patient-specific prostate cancer education. The tool delivers clear explanations based on each patient's health record, improving confidence and understanding of diagnosis and treatment options.
Mayo Clinic researchers developed an AI-ECG model that accurately diagnoses advanced chronic liver disease, allowing for early intervention and potential lifesaving treatment. The study found the model detected twice as many cases as standard methods, highlighting the promise of AI in preventive care.
A new multicenter study led by Mayo Clinic researchers has established a practical definition for rapidly progressive dementia (RPD), a rare but devastating form of cognitive decline. The findings may help clinicians recognize and treat RPD earlier, enabling researchers to work from a shared framework when studying the condition.
Researchers found that mitochondrial RNA can leak into healthy tissue, triggering inflammation and scarring. Inhibiting certain proteins enables mitochondrial RNA to escape, leading to less inflammation and healthier liver tissue.
Researchers at Mayo Clinic have developed a smartwatch-based alert system that signals parents to intervene in children with emotional and behavioral disorders, reducing tantrum duration by an average of 11 minutes. The system uses physiological stress signals detected by the smartwatch to prompt parental intervention.